P
Pulike Biological Engineering Inc
SSE:603566
Pulike Biological Engineering Inc
SSE:603566
Price:
12.32
CNY
-3.45%
Market Cap:
¥4.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Pulike Biological Engineering Inc
SSE:603566
|
CN |
|
T
|
Telecom Digital Holdings Ltd
HKEX:6033
|
HK |
|
Standard BioTools Inc
NASDAQ:LAB
|
US |
|
Jiangxi Black Cat Carbon Black Inc Ltd
SZSE:002068
|
CN |
|
F
|
First Republic Bank
BMV:FRC
|
US |
|
Compagnie Financiere Tradition SA
F:CFI
|
CH |
|
Cortina Holdings Ltd
SGX:C41
|
SG |
|
Diageo PLC
LSE:DGE
|
UK |
|
Halo Food Co Ltd
ASX:HLF
|
AU |
|
Just Life Group Ltd
NZX:JLG
|
NZ |
|
C
|
CNlight Co Ltd
SZSE:002076
|
CN |
|
IDEX Corp
NYSE:IEX
|
US |
|
Dlocal Ltd
NASDAQ:DLO
|
UY |
|
MBIA Inc
NYSE:MBI
|
US |
|
G
|
Greenpanel Industries Ltd
NSE:GREENPANEL
|
IN |
|
Novacyt SA
PAR:ALNOV
|
FR |
|
B
|
Bank Of Princeton
NASDAQ:BPRN
|
US |
Multiples-Based Value
The Multiples-Based Value of one Pulike Biological Engineering Inc stock under the Base Case scenario is hidden CNY. Compared to the current market price of 12.32 CNY, Pulike Biological Engineering Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Pulike Biological Engineering Inc Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Pulike Biological Engineering Inc Competitors
Pulike Biological Engineering Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
P
|
Pulike Biological Engineering Inc
SSE:603566
|
4.3B CNY | 3.9 | 29.7 | 23.7 | 23.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.2 | 21.6 | 15 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 20.4 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
